Evidence map›Paper›PMID 40954938›Full record

ArticleCatheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions2025

Noncoronary Sinus Pivot Implantation (NCPI) Strategy for Transcatheter Aortic Valve Replacement With Self-Expanding Valve in Pure Native Aortic Regurgitation: A Multicenter, Registry Study From the CCA Database-NTCVR.

Feng Xia, XinJing Chen, ZiLong Weng, Xin Pan, JinJun Liu, Hao Zhou, LianPin Wu, YanSong Guo, LongYan Zhang, WenZhi Pan and 2 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Feng XiaDepartment of Cardiology, Wuhan Asia General Hospital, Wuhan, China.
XinJing ChenDepartment of Cardiology, Provincial Clinical Medical College of Fujian Medical University, Fuzhou University Affiliated Provincial Hospital, Fuzhou, China.
ZiLong WengDepartment of Cardiology, Zhongshan Hospital, Fudan University, Shanghai, China.
Xin PanDepartment of Cardiology, Shanghai Chest Hospital Affiliated With Shanghai Jiao Tong University, Shanghai, China.
JinJun LiuDepartment of Cardiology, The First Affiliated Hospital of Bengbu Medical College, Bengbu, China.
Hao ZhouDepartment of Cardiology, The First Affiliated Hospital, Wenzhou Medical University, Wenzhou, China.
LianPin WuDepartment of Cardiology, The Second Affiliated Hospital, Wenzhou Medical University, Wenzhou, China.
YanSong GuoDepartment of Cardiology, Provincial Clinical Medical College of Fujian Medical University, Fuzhou University Affiliated Provincial Hospital, Fuzhou, China.
LongYan ZhangDepartment of Cardiology, Wuhan Asia General Hospital, Wuhan, China.
WenZhi PanDepartment of Cardiology, Zhongshan Hospital, Fudan University, Shanghai, China.ORCID 0000-0002-0530-261X
DaXin ZhouDepartment of Cardiology, Zhongshan Hospital, Fudan University, Shanghai, China.ORCID 0009-0007-9814-3630
JunBo GeDepartment of Cardiology, Zhongshan Hospital, Fudan University, Shanghai, China.ORCID 0000-0002-9360-7332

Funding

This study was supported by the National Natural Science Foundation of China (No. NSFC 82270377), Fujian Science and Technology Innovation Joint Funding Project Plan (No. 2024Y9010), and Fujian Provincial Natural Science Funding Project (No. 2025J01068).
6 · The paper itself

Abstract

backgroundTranscatheter aortic valve replacement (TAVR) for pure native aortic regurgitation (PNAR) remains challenging. While the noncoronary sinus pivot implantation (NCPI) strategy showed promise with VitaFlow valve, its efficacy with other valves needs validation.

aimsThis study aims to evaluate the real-world efficacy of the TaurusElite valve in patients with PNAR and to assess the impact of the NCPI strategy on procedural outcomes.

methodsThis registry-based analysis included 121 PNAR patients from the prospective CCA Database-NTCVR who underwent transfemoral TAVR with TaurusElite valve at seven Chinese centers (April 2022 to October 2024). A core laboratory assessed procedural imaging to classify patients into NCPI (n = 81) and non-NCPI (n = 37) groups. Outcomes were evaluated per VARC-3 criteria.

resultsThe TaurusElite valve demonstrated good effectiveness (overall device success 90.9%). NCPI strategy showed superior outcomes: higher success rate (98.8% vs. 81.1%, p < 0.001), no valve-in-valve implantation (0% vs. 16.2%, p < 0.001), and lower permanent pacemaker requirement (3.7% vs. 18.9%, p = 0.006). NCPI (OR:6.08, 95% CI: 3.27-28.68) independently predicted success.

conclusionsThe TaurusElite valve is an effective treatment for PNAR, and the NCPI strategy provides significant additional benefits in improving procedural success and reducing complications compared to conventional approaches.

Indexed as

Aortic ValveAortic Valve InsufficiencyHeart Valve ProsthesisTranscatheter Aortic Valve ReplacementAgedAged, 80 and overChinaDatabases, FactualFemaleHumansMaleProspective StudiesProsthesis DesignRecovery of FunctionRegistriesRisk Factorsaortic regurgitationclinical outcomesimplantation techniqueself‐expanding valvetranscatheter aortic valve replacement

Identifiers

PMID40954938
PMCPMC12617326

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.